^
    Back
    Association details:
    Biomarker:CD93 underexpression
    Cancer:Urothelial Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Front Mol Biosci
    Title:

    Pan-Cancer Analysis Identified CD93 as a Valuable Biomarker for Predicting Patient Prognosis and Immunotherapy Response

    Published date:
    02/21/2022
    Excerpt:
    ...patients with a low expression of CD93 were more sensitive to immunotherapy in urothelial cancer.
    DOI:
    10.3389/fmolb.2021.793445